Press Release FeedGet the RSS feed
Menu

Business Wire

Foundation Medicine’s FoundationOne®MRD Named a 2026 Top Innovation Winner by The Scientist

Business Wire

First-of-its-kind molecular residual disease test combining structural variants and digital PCR recognized for enabling ultra-sensitive molecular disease detection, with high specificity, in the Healthcare and Diagnostics category

BOSTON, October 23, 2026--Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that its molecular residual disease (MRD) assay, FoundationOne®MRD,1 has been selected as a winner in The Scientist's 2026 Top Innovations Contest. Recognized specifically within the Healthcare and Diagnostics category, the honor highlights the most transformative and useful advances in life science techniques and products.

FoundationOne MRD is the first MRD test to combine structural variants and digital PCR, enabling ultra-sensitive MRD detection, with high specificity.2 FoundationOne MRD leverages a differentiated approach designed to deliver highly sensitive and specific MRD detection alongside an accelerated turnaround time for healthcare providers. The personalized tumor fingerprint and initial blood test can be expected within approximately 2 to 3 weeks from the sample receipt, and subsequent blood test results can be anticipated within 1 to 3 days. The test is currently covered by Medicare for recurrence monitoring in patients with stage II - III breast cancer across all subtypes.

"We are deeply honored that independent experts from The Scientist have validated the clinical vision behind FoundationOne MRD," said Vera Grossmann, interim chief executive officer and chief operating officer at Foundation Medicine. "This award underscores our relentless dedication to precision medicine. By pairing structural variant sequencing with digital PCR, we provide healthcare providers with a tool that delivers speed and specificity, allowing them to intervene earlier and personalize treatment pathways when every day counts."

Selected from a competitive pool by an independent panel of judges, the winning innovations reflect the most exciting technologies launched between March 2025 and March 2026.

For more information on Foundation Medicine's suite of diagnostic tools to empower healthcare providers to identify disease recurrence earlier, select the best therapies for patients and monitor treatment response over time, explore the company's portfolio of tests.

About Foundation Medicine

Foundation Medicine is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and other diseases. We provide tests and solutions to transform care throughout a patient's experience, from defining a diagnosis to determining the appropriate treatment to ongoing monitoring. We help accelerate the development of new personalized therapies by leveraging our vast knowledge of precision medicine, real world data and AI-powered tools, expanding the information our diagnostic solutions provide to enable improved outcomes for patients. Every day, we are inspired to think differently to transform the lives of people living with cancer and other diseases. For more information, visit us at www.FoundationMedicine.com and follow us on LinkedIn, X, YouTube, Facebook, Instagram and BlueSky.

  1. FinanceSierra BancorpSierra Bancorp Announces Share Repurchase Program and Declares Quarterly Cash DividendPORTERVILLE, Calif., October 23, 2026--Sierra Bancorp (Nasdaq: BSRR), parent of Bank of the Sierra, announced that its Board of Directors has approved a new share repurchase program authorizing the Company to repurchase up to one million (1,000,000) shares of its outstanding common stock, from time to
  2. FinanceOklo Inc.Oklo Announces Date for Third Quarter 2026 Financial Results and Business Update CallSANTA CLARA, Calif., October 23, 2026--Oklo Inc. (NYSE: OKLO) ("Oklo," or "the Company"), an advanced nuclear technology company, today announced it will release its financial results and provide business updates for the third quarter ended September 30, 2026, before market opens on Friday, November 6,
  3. FinanceMarcus & Millichap, Inc.Marcus & Millichap, Inc. to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026CALABASAS, Calif., October 23, 2026--Marcus & Millichap, Inc. (NYSE: MMI), a leading national brokerage firm specializing in commercial real estate investment sales, financing and research and advisory services, announced today it will report its financial results for the third quarter ended September
  4. FinanceEvolv Technologies Holdings, Inc.Evolv Technology Enters Subscription Agreement With Utah Jazz, Utah Mammoth, and the Delta CenterDeployment of Evolv Express ® and Evolv eXpedite™ adds Salt Lake City to Evolv's growing dual-sport arena customer roster WALTHAM, Mass., October 23, 2026--Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), a leading security technology company pioneering AI-powered solutions designed to create safer ex
  5. BankingBankjoyTEN Credit Union Selects Bankjoy for Digital Banking as It Moves to Corelation KeyStoneNashville credit union will launch Bankjoy on the same day as its KeyStone conversion DETROIT, October 23, 2026--Bankjoy , a leading provider of digital banking solutions for community financial institutions, today announced that TEN Credit Union (TENCU), a Nashville-based credit union founded in 1950
  6. FinanceRepublic Bancorp, Inc.Republic Bancorp Reports Solid Third Quarter Results Highlighted by Continued Strong Core Banking Net Interest Income ExpansionLOUISVILLE, Ky., October 23, 2026--Republic Bancorp, Inc. ("Republic" or the "Company") reported third quarter 2026 net income and Diluted Earnings per Class A Common Share ("Diluted EPS") of $31.1 million and $1.59, representing increases of 4% and 5% from the $29.7 million and $1.52 reported for the